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Abstract
Recent expert guidelines recommend genetic testing for the diagnosis of Alport syndrome. Here, we describe current best practice
and likely future developments. In individuals with suspected Alport syndrome, all three COL4A5, COL4A3 and COL4A4 genes
should be examined for pathogenic variants, probably by high throughput-targeted next generation sequencing (NGS) technol-
ogies, with a customised panel for simultaneous testing of the three Alport genes. These techniques identify up to 95% of
pathogenic COL4A variants. Where causative pathogenic variants cannot be demonstrated, the DNA should be examined for
deletions or insertions by re-examining the NGS sequencing data or with multiplex ligation-dependent probe amplification
(MLPA). These techniques identify a further 5% of variants, and the remaining few changes include deep intronic splicing
variants or cases of somatic mosaicism. Where no pathogenic variants are found, the basis for the clinical diagnosis should be
reviewed. Genes in which mutations produce similar clinical features to Alport syndrome (resulting in focal and segmental
glomerulosclerosis, complement pathway disorders, MYH9-related disorders, etc.) should be examined. NGS approaches have
identified novel combinations of pathogenic variants in Alport syndrome. Two variants, with one in COL4A3 and another in
COL4A4, produce a more severe phenotype than an uncomplicated heterozygous change. NGS may also identify further
coincidental pathogenic variants in genes for podocyte-expressed proteins that also modify the phenotype. Our understanding
of the genetics of Alport syndrome is evolving rapidly, and both genetic and non-genetic factors are likely to contribute to the
observed phenotypic variability.
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Introduction
Alport syndrome is an inherited glomerular disease
characterised by haematuria, progressive renal failure, hearing
loss and ocular abnormalities [1, 2]. It is the second most
common cause of monogenic kidney failure after autosomal
dominant polycystic kidney disease [3]. Eighty-five percent of
families have X-linked inheritance with COL4A5 mutations,
and 15% have autosomal recessive disease, with two muta-
tions in COL4A3 or COL4A4 in trans, that is, on different
chromosomes [4–6].
The demonstration of a pathogenic COL4A5 variant con-
firms the diagnosis of X-linked Alport syndrome, and the
demonstration of two COL4A3 or COL4A4 pathogenic vari-
ants confirms the diagnosis of autosomal recessive Alport
syndrome [7]. Establishing the mode of inheritance is impor-
tant for genetic counselling, for identifying other at-risk family
members, for determining the affected status of potential
living-related kidney donors, and for enabling prenatal and
preimplantation genetic diagnosis. Some mutations (inser-
tions, deletions, nonsense and splicing mutations, Gly
The following guidelines were developed by an international group of
expert adult and paediatric physicians, geneticists and researchers who
work on Alport syndrome, and met for discussion at the Second Alport
syndrome meeting in Gottingen, Germany in 2015 and at Glagow, UK in
2017. The guidelines have been further refined until a consensus was
reached after a year of email discussions. These guidelines are
complementary to the ‘Expert guidelines on the diagnosis and
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substitutions, with Arg, Glu or Asp) increase the likelihood
of a severe phenotype with early-onset renal failure,
lenticonus and central fleck retinopathy [8–10]. This
genotype-phenotype correlation holds true for males with
X-linked inheritance, and also for males and females with
autosomal recessive disease [11]. In addition, the presence
of a large deletion in COL4A5 indicates a small but in-
creased risk of antiglomerular basement membrane
(GBM) disease post-transplantation [12–14]. Furthermore,
the type of mutation is also likely to indicate future thera-
pies, which will target mutation types, namely missense or
nonsense variants.
The lack of a consensus on the the use of ‘autosomal
dominant (AD) Alport syndrome’ for individuals with het-
erozygous COL4A3 or COL4A4mutations is because most
do not have a hearing loss, ocular abnormalities, or a
lamellated glomerular basement membrane (GBM) and
few develop end-stage renal failure [7, 15]. However, their
prognosis is not necessarily benign and a small but unpre-
dictable number have kidney failure [16, 17]. There is no
obvious explanation for this when most other family mem-
bers with the same mutations have life-long normal renal
function. This discrepancy suggests that these cases of
renal failure are not wholly genetic but have other causes
too. It is usually not possible to exclude a second unde-
tected mutation in the COL4A3/COL4A4 genes in reported
cases. The likelihood of renal failure itself is very small,
and the diagnosis of Alport syndrome with all its implica-
tions would cause unnecessary anxiety when renal func-
tion will usually remain normal. In addition, the use of the
term AD disease for carriers of a recessively inherited
condition is not common practice. It was for these reasons
that the group behind the Expert guidelines chose not to
use the term ‘AD Alport syndrome’ until the effects of
modifying mutations, coincidental renal disease and other
complicating factors (smoking, hypertension, diabetes
and obesity) are better understood. The Expert guidelines
also continue to advocate the use of ‘Thin basement mem-
brane nephropathy’ while recognising its limitations.
Although not ideal, the term ‘Thin basement membrane
nephropathy is widely understood.
The recent widespread adoption of next generation se-
quencing (NGS) technologies (Table 1) by routine diagnostic
laboratories has demonstrated manymore pathogenic and nor-
mal DNAvariants in the genes affected in Alport syndrome. It
has also indicated that the genetics of Alport syndrome is
complicated, with different combinations of variants in the
collagen IV genes, and digenic variants in the collagen IV
and other podocyte genes, all potentially affecting the pheno-
type [16, 18, 19]. The international community involved in
Alport gene testing has responded to developments by pro-
ducing these consensus guidelines for renal physicians and
laboratories that test for Alport mutations.
Testing strategy for Alport syndrome
Alport syndrome is underdiagnosed. We know this because
most reported series comprise mainly men and yet women are
affected twice as often with X-linked disease [20]. Alport
syndrome is suspected in an individual with persistent
haematuria, proteinuria and/or renal impairment; with early-
onset hearing loss, or peripheral retinopathy; or with a family
history of Alport syndrome, or a family history of haematuria,
renal impairment and no other obvious cause [7]. The pres-
ence of lenticonus, a central or peripheral retinopathy, a giant
macular hole or temporal retinal thinning, are all pathogno-
monic [21]. The presence of any one of the diagnostic criteria
(lamellated GBM, hearing loss, lenticonus, fleck retinopathy)
is likely to result in a positive genetic test [22]. However,
genetic testing has demonstrated that COL4A3, COL4A4 or
COL4A5mutations are also found in more than 30% of adult-
onset familial focal and segmental glomerulosclerosis (FSGS)
[23, 24]. In addition, Alport syndrome and thin basement
membrane nephropathy commonly coexist with IgA
Table 1 Glossary of terms
A ‘normal DNA variant’ is a variant that occurs in many normal
individuals without causing disease. This contrasts with a ‘pathogenic’
or ‘disease-causing variant’.
‘Next generation sequencing’ (NGS) refers to all forms of massively-
parallel sequencing, namely, targeted gene panels, WES (where the
exons and adjacent intronic regions of all genes are sequenced) and
whole genome sequencing (where exons, introns and intergenic
regions are sequenced).
‘Whole exome sequencing’ (WES) - all the exons in all of the genes in the
genome are sequenced.
‘Clinical exome’ sequencing - the exons of an inclusive set of genes
previously associated with human disease.
A ‘targeted NGS panel’ might include 30–50 genes affected
in diseases causing a certain phenotype, such as proteinuria,
haematuria; or just COL4A5, COL4A3 and COL4A4 in the case of
Alport syndrome.
An ‘NGS panel’ might use a multiple PCR or capture array
for enrichment.
‘Sanger sequencing’ -typically only the exons of one or a few
genes are sequenced.
‘Cis’ and ‘trans’- where two DNA variants are found in a gene on
the same chromosome (cis) or different (trans) chromosomes.
Generally the two mutations in autosomal recessive Alport
syndrome are found on different chromosomes. When both
mutations are found on the same chromosome the effect is
less severe. The usual way to distinguish between cis and trans
is to sequence the maternal and paternal chromosomes.
Mutations in cis are inherited together from one parent.
Mutations in trans have been inherited one from each parent.
‘Biallelic’- pathogenic variants in both alleles of a gene (that is, in trans)
‘Digenic’- pathogenic variants in two different genes
A ‘minigene’ is a gene fragment that includes an exon or exons and
introns, together with the control regions for expression. Minigenes
are useful in evaluating splicing variants.
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glomerulonephritis [25] but may be overlooked because the
renal biopsy is not examined for GBM lamellation or thinning
by electron microscopy.
Recommendation 1: Individuals with haematuria and
a lamellated GBM or hearing loss, lenticonus or a
fleck retinopathy are likely to have Alport syndrome
and should be offered genetic testing for mutations in
all three Alport genes (COL4A5, COL4A3 and
COL4A4). Individuals with focal and segmental
glomerulosclerosis (FSGS) should also be offered ge-
netic testing for mutations in the Alport genes in addi-
tion to podocyte-related genes. Cascade testing should
be performed in at risk family members of an individ-
ual with X-linked Alport syndrome or a COL4A5
mutation.
The diagnosis of Alport syndrome is particularly difficult
when there are no extrarenal manifestations and proteinuria
predominates. The best approach is to have a high index of
suspicion for the diagnosis. Alport syndrome is common.
What else could the diagnosis be? Testing the parents for
haematuria is often rewarding.
Assessment of the patient with suspected Alport syndrome
should include audiometry, ophthalmological review, retinal
imaging and, possibly, retinal optical coherence tomography
(OCT) [21, 26]. The ocular features are evident in the most
severe cases from adolescence, so it is worthwhile examining
the mother’s retina when a boy presents with suspected X-
linked disease. (The father of an affected girl will usually have
been diagnosed by this time.) The retinal changes are asymp-
tomatic and do not affect vision [27, 28]. Audiometry is
worthwhile, both diagnostically and to confirm the need for
a hearing aid, in all individuals with suspected Alport syn-
drome, and should be repeated as often as clinically indicated.
Individuals may undergo renal biopsy to demonstrate
the lamellated GBM typical of Alport syndrome [7].
However, the GBM is often thinned in boys and females,
and can be atypical with some mutations. Some laborato-
ries also examine the GBM or skin for collagen IV α5
staining [29, 30], but this technique may be difficult to
interpret.
Genetic testing is more sensitive and specific for the diag-
nosis of Alport syndrome than renal biopsy [7], and provides
predictive information about disease severity and prognosis.
However a renal biopsy also indicates the amount of glomer-
ular and tubular interstitial damage, and the presence of other
abnormalities such as IgA glomerulonephritis or FSGS.
Usefulness of identifying genetic mutations
The demonstration of a pathogenic variant in COL4A5
or two pathogenic variants in trans in COL4A3 or
COL4A4 confirms the diagnosis of Alport syndrome. It
also confirms inheritance as X-linked or autosomal re-
cessive. The mode of inheritance indicates who else in
the family is at-risk and whether the disease may recur
in subsequent generations. Knowing the mutation in a
family facilitates cascade testing for other family mem-
bers. Testing may demonstrate that a family member
does not have the pathogenic mutation and could act
as a kidney donor to an affected relative. Identification
of the causative variant is required for prenatal and pre-
implantation genetic diagnosis (PGD).
Knowledge of the causative mutation often indicates
the likely clinical course. Thus ‘severe’ mutations in X-
linked disease, including insertions/deletions, nonsense
mutations, rearrangements with frameshifts or splicing
mutations, result in early-onset renal failure, before the
age of 30 years [8–11], as well as increased extrarenal
features, such as ocular abnormalities and aortic aneu-
rysms [31]. Substitutions of Gly with a charged residue,
such as Arg, Glu or Asp, also result in early-onset renal
failure and more extrarenal features [32]. In addition,
some men with X-linked disease have an increased risk
of developing antiGBM disease post-transplantation, es-
pecially those with large deletions. Clinical features in
women with X-linked disease correlate less well with
mutation severity, probably because of random X-
chromosomal inactivation (lyonization), while coinciden-
tal factors such as preeclampsia, infections, hypertension
and nephrotoxic agents may exacerbate renal impairment
[33].
The same genotype-phenotype correlations also occur
with autosomal recessive disease: the age at end-stage
renal failure is younger for an individual with two se-
vere mutations than with one, and younger for a person
with one than none [11, 34] where severity is defined as
for the COL4A5 mutations. In addition, extrarenal fea-
tures are more common with two severe mutations than
with one or none [11]. A younger age at onset of renal
failure and extra renal complications are also found with
substitutions of Gly by Arg, Glu or Asp.
Another advantage of genetic testing is that generic
treatments based on mutation type (missense or non-
sense) may soon be available. For example, chemical
chaperones may be useful in treating Alport syndrome
due to missense mutations [35], and inhibitors of
nonsense-mediated decay (puromycin, anisomycin etc.)
in disease due to nonsense mutations [36]. These treat-
ments will not be curative but may slow the rate of
deterioration to end-stage renal failure.
Mutation testing in Alport syndrome
In general, mutations are different in each family with Alport
syndrome and there are no mutation ‘hot spots’ in the affected
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genes, except for the Gly residues in the collagenous interme-
diate domain [11]. Founder mutations (variants that are de-
scribed more than five times in apparently unrelated families)
have been reported in North American [37], British [34],
Cypriot [38] and Eastern European [39] cohorts. Within a
single pedigree, the mutation is the same in all affected mem-
bers but some families include individuals with renal failure
from a different cause. In addition, we have seen different
second mutations in cousins who both had autosomal reces-
sive Alport syndrome [34].
The COL4A5, COL4A3 and COL4A4 genes are enormous
with 53, 52 and 48 exons respectively, and conventional
Sanger sequencing of all the exons is very labour-intensive.
Many more COL4A5 variants have been reported (n = 1900)
than for COL4A3 and COL4A4 (n = 600) [40], but only 10%
of all possible pathogenic COL4A5 variants are estimated to
be known [1].
Evidence from testing laboratories suggests that 75% of
pathogenic variants found are novel changes [17, 41]. In X-
linked disease, about 40% of all mutations are missense,
10% are splicing mutations, 7% are nonsense mutations,
and a further 30% result in a frameshift and downstream
nonsense change, meaning that nearly 40% of all variants
produce nonsense mutations [11, 42]. Similar proportions of
pathogenic variants are seen in autosomal recessive disease.
The most common mutations are Gly substitutions. They
are usually pathogenic if they affect a Gly in the intermediate
collagenous domain, since Gly is the smallest amino acid and
replacement with a larger residue disrupts the triple helical
structure. Few Gly substitutions are non-pathogenic. It is
much more difficult to distinguish between pathogenic and
benign variants for non-Gly substitutions.
There is only one report of a mutation in the COL4A5
promoter, and the only COL4A6mutations that are associated
with Alport syndrome are large, contiguous deletions that ex-
tend from COL4A6 into COL4A5 [11]. Where deletions in-
volve intron 2, they result in leiomyomatosis. There is no
evidence that isolated COL4A6 missense mutations produce
the Alport phenotype, nor is there evidence for any other gene
loci for Alport syndrome other than COL4A5/COL4A6 and
COL4A3/COL4A4. Nevertheless, rare mutations in other
GBM or podocyte genes appear to produce a lamellated
GBM in humans and in animal models [43].
Genotype-phenotype correlations
The commonly used DNA variant databases often include
little clinical data, because many of their so-called nor-
mals have not been physically examined or the requests
for testing include limited clinical information. In addi-
tion, most databases accept the submitters’ assessments
of pathogenicity and phenotype. Despite these limitations,
databases have contributed greatly to genotype-phenotype
correlations [11].
Recommendation 2: All three COL4A5, COL4A3 and
COL4A44 genes should be examined in individuals un-
dergoing genetic testing for Alport syndrome. This can
be by high throughput sequencing of a custom panel
includingCOL4A5,COL4A3 andCOL4A4 byWES, or
by Sanger sequencing.
Three studies of NGS from different laboratories
have confirmed that the mode of inheritance is difficult
to predict clinically [17, 41, 44]. This is the reason that
all three COL4A5, COL4A3 and COL4A4 genes are rec-
ommended for testing in suspected Alport syndrome.
NGS detects nearly 95% of all missense and nonsense
variants, insertions and deletions, and most splicing var-
iants near intron-exon boundaries [16, 41]. NGS detects
variants in COL4A5, COL4A3 and COL4A4, and other
genes, simultaneously, which is important with the in-
creasing recognition of biallelic and digenic variants in
Alport syndrome. Duplications, insertions, and deletions
account for 5–10% of all pathogenic variants in Alport
syndrome, but sequencing is less sensitive for their de-
tection. One study has used the Integrative Genomics
Viewer to retrospectively identify insertions and dele-
tions that were previously only found with Sanger se-
quencing [41].
Recommendation 3: Another technique, such as multi-
plex ligation-dependent probe amplification (MLPA),
may be required to detect duplications, insertions and
deletions, but NGS approaches on different platforms
may be configured to ensure sufficient read coverage to
detect these.
Recommendation 4: When a COL4 mutation cannot
be demonstrated in an individual with suspected
Alport syndrome, then the diagnosis and supporting
features (GBM appearance, retinal photographs and
retinal optical coherence tomography demonstration
of temporal thinning) should be reviewed. Some of
these individuals will have deep intronic splicing mu-
tations or genetic mosaicism, which both require fur-
ther specialised tests for their detection.
Deep intronic variants that introduce splicing defects
often require whole genomic sequencing or a splicing
assay for their detection. Deep intronic variants have
been detected by sequencing [46], but splice site testing
is typically performed using hair root cDNA [47–50] to
confirm COL4A5 variants, or lymphocyte cDNA [51]
for COL4A3/COL4A4 variants. The hair roots are stable
for days at room temperature, but must be of sufficient
number, and the nested primer design is critical.
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Alternatively, the pathogenicity of a splicing COL4 var-
iant may be demonstrated with a ‘hybrid minigene’, a
method that has a strong concordance with native RNA
examination [52–54]. The low level of mRNA is some-
times problematic but the strategy is to use easily ac-
cessible tissues such as skin or peripheral blood to as-
sess whether the wild-type transcript is produced [16].
Constructs containing DNA sequences from control and
mutant genes are transiently transfected in a cell line
(the HEK cells mimics the kidney splicing environment)
where the minigene is transcribed. mRNA splicing pat-
terns corresponding to wild type and to the mutant al-
lele are then compared by RT-PCR analysis and se-
quencing of the amplification products [55]. These as-
says are relatively easy to perform but few diagnostic
laboratories have the necessary experience.
Mosaicism is usually associated with milder clinical fea-
tures. It occurred in nearly 10% of families (3/28) in one series
[56–58], but is difficult to detect because of reduced mutant
COL4A5 expression. High-depth NGS overcomes this limita-
tion and will indicate the real impact of this phenomenon in
Alport syndrome. Mosaicism can also be demonstrated in
males with X-linked Alport syndrome by skin or renal immu-
nohistochemistry. The diagnosis of mosaicism has important
consequences for patient management and genetic counselling
[59, 60].
Description of DNA variants
Recommendation 5:All variants are described accord-
ing to the normal reference nucleotide and amino acid
sequences (Locus Reference Genomic (LRG) se-
quence, http:www.irg-sequence.org/) which are
agreed upon by an international expert panel and
updated regularly. Variants are described using the
nomenclature recommended by the Human Genome
Variation Society (HGVS) (http://www.hgvs.org/
mutnomen/), and confirmed with on-line tools such
as Mutalyzer that check residue number and
descriptions (http://mutalyzer.nl/).
The uniform nomenclature is informed by standardised
criteria to ensure an unambiguous designation for any variant.
This standard has been adopted internationally for all refer-
ence sequences. Thus, the longer sequence for COL4A5
(LRG_232t2, NM_033380) with 53 exons is now used. The
two extra exons each have 9 nucleotides or three codons and
are located immediately after exon 41. The corresponding
transcript is found in the kidney but only one mutation affect-
ing this region has been reported to date. This change in the
reference sequence means that variants reported before 2014
in exons 42–51 now have a new description. It is worthwhile
confirming that any variants in exons 42–53 of COL4A5 are
aligned to the correct reference sequence. For a quick conver-
sion, for nucleotides after 3790 in COL4A5, 18 base pairs are
added to the 51 exon nomenclature (ARUP, HGMD) to obtain
the 53 exon nomenclature (LOVD). For amino acids beyond
1264, 6 amino acids are added to the 51 nomenclature.
How to distinguish between a pathogenic
and a benign variant
The majority of likely pathogenic variants identified in the
Alport genes by testing laboratories are novel [17, 41, 44].
Standards and guidelines are used to assess likely pathogenic-
ity [61, 62]. Assessments should be performed by qualified
and experienced staff, and multiple lines of evidence used for
all Alport genes [61] (Table 2). However, variant interpreta-
tion is not static, and a variant currently determined to be of
‘unknown significance’may be reclassified to ‘pathogenic’ or
‘normal’ as further information becomes available. Thus, as-
sessments of pathogenicity will be corrected over time. There
is no coordinating group of clinicians and scientists that con-
firms pathogenicity evaluations as there is for some mutations
in cancer. However, principles for identifying pathogenicity
for variants including in the collagen genes are slowly emerg-
ing. General guidelines have been developed in both the USA
and Europe but those from the USA are probably more widely
used [61] (Table 3).
Recommendation 6: Likely deleterious variants in the
Alport genes
Variants in the Alport genes are more likely to be del-
eterious if they are:
Exonic deletions/insertions or duplications
Nonsense variants. However, caution is needed in the
unusual circumstances where a predicted stop codon is
in the last exon or in the last 50 bp of the penultimate
exon so that nonsense-mediated decay does not occur,
and the protein is more likely to be expressed;
Frameshift variants. Again caution is needed where an
insertion or deletion is followed closely by a change that
cancels the frameshift; or where the predicted stop codon
occurs in the last exon or in the last 50 bp of the penulti-
mate exon.
Mutations affecting the consensus splicing sites (± 1 or 2
nucleotides). However, again an inframe deletion/
insertion may retain the critical domains of the protein;
Glycine missense variants in the intermediate collage-
nous domains (with Gly Xaa-Yaa repeats). But not if they
affect Gly in one of the short non-collagenous interrup-
tions. Thus, rarely, some Gly substitutions (p.Gly624Asp
in COL4A5) are not pathogenic.
New DNA variants in apparently sporadic disease, that














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The assessment of other variants (non-Gly substitutions,
other missense variants, deep intronic, intronic, inframe dele-
tions/duplication/insertions/indels) may be more problematic.
Laboratories typically use bioinformatics software to assess
pathogenicity [63] including Alamut (v2.3 Rouen, France),
Ingenuity (www.ingenuity.com) and in-house algorithms.
Genetic evidence for pathogenicity [63]
In general, there is no gold standard that defines pathogenicity.
There is no single test that indicates with absolute certainty
that a variant is pathogenic. Pathogenicity is defined more on
probability using a number of criteria.
1. The variant has been described previously as pathogenic
in a disease or variant database. Searching a curated and
current locus-specific database (LSDB) that includes clin-
ical associations, for example, the LOVD and
Professional HGMD databases is considered essential
(Table 2). Searching the relevant literature (PubMED,
GoogleScholar, OMIM, Google search) for the variant is
recommended. However, many variants have not been
formally assessed and some assessments (including both
the numbering and the interpretation of variants) are in-
correct so these results are not definitive [63]. In addition
the errors may be repeated in different databases.
2. The variant is absent or at very low frequency in large
population cohorts with similar ancestry (1000 genomes;
ExAC, gnomAD). Essential.
3. The variant is sporadic (not found in the parents, especial-
ly in X-linked Alport syndrome) but is still coincident
with disease. Acceptable.
4. Co-segregation of variants with the disease within the fam-
ily. Affected and definitely unaffected family members are
equally useful for this type of assessment. Segregation is
based on the haematuria in Alport syndrome being fully-
penetrant from infancy which is true at least for COL4A5-
associated disease. This approach is also useful in exclud-
ing pathogenicity. Acceptable.
5. The variant is enriched in affected individuals compared
with controls. This is the least useful recommendation in
Alport syndrome because some community-based indi-
viduals with Alport syndrome are undiagnosed and some
normal variants are underreported, especially in non-
Caucasians. This is also a problem with autosomal reces-
sive disease where pathogenic variants may occur at a
high carrier frequency in certain populations. Acceptable.
Bioinformatic evidence for pathogenicity
6. The variant affects a site that is evolutionarily conserved



















































































































































































































Table 3 ACMG classification of pathogenic and benign variants
Pathogenic Applicability to Alport syndrome
Very strong evidence of pathogenicity
PVS1 Null variant: nonsense, frameshift, canonical ± 1 or 2 splice sites, initiation
codon, single or multi-exon deletion
Yes
Strong evidence of pathogenicity
PS1 Same aa change as a previously-demonstrated pathogenic variant but caused by a
different nucleotide change
Yes
PS2 De novo variant in only affected individual with no family history and both
maternity and paternity confirmed
Yes
PS3 Well-established in vitro or in vivo functional studies confirm damaging effect Splicing mutations only
PS4 Prevalence of variant is increased in affected individuals compared with controls
(say, OR > 5.0)
Yes
Moderate evidence of pathogenicity
PM1 Variant located withinmutational hotspot or functional domain that is not affected
by benign variants
Gly residues in intermediate collagenous domain are critical
PM2 Variant absent from controls in Exome sequencing Project (ESP), 1000 genomes,
ExAC, gnomAD
Yes
PM3 For AR AS, variant detected in trans with a pathogenic variant. This requires
testing of parents or offspring
Yes
PM4 Protein length changes because of inframe deletions/insertions Yes
PM5 Novel missense change at aa where a different pathogenic change has been noted
previously
Yes
PM6 Assumed de novo, but without confirmation of maternity and paternity Yes
Supporting evidence of pathogenicity
PP1 Co-segregation with disease in multiple affected family members Yes
PP2 Missense variant in gene where missense variants cause disease but benign
missense variants are uncommon
Many pathogenic and benign missense variants in Alport
syndrome
PP3 Evidence from different computational strategies Yes
PP4 Phenotype is highly specific for disease Yes
PP5 Reputable source reports variant to be pathogenic but evidence not available Yes
Benign
Stand-alone evidence of benign impact
BA1 Allele frequency > 5% in ESP, 1000 Genomes, ExAC, gnomAD Yes
Strong evidence of benign impact
BS1 Allele frequency is more than expected Yes
BS2 Observed in healthy adults where penetrance is expected at a younger age Haematuria is most sensitive marker and found in nearly all
adults with pathogenic variant
BS3 Well-established in vitro or in vivo functional studies indicate no damaging effect Only studies for splicing; no other assays
BS4 Lack of segregation in an affected family Yes
Supporting evidence of benign impact
BP1 Missense variant in gene where all variants are truncating Not applicable
BP2 Observed in cis with a pathogenic variant Yes
BP3 Inframe deletions/insertions in a repetitive region without known function Not applicable
BP4 No impact in computational studies Yes
BP5 Variant found in individual with alternate molecular basis for disease Yes (other podocyte genes)
BP6 Reputable source reports variant to be benign but evidence not available Yes
BP7 A synonymous variant where splicing prediction algorithm predicts no effect
AND the nucleotide is not highly conserved
Yes
Modified from Tables 3 and 4, Richards et al. [61] (used with permission)
aa amino acid
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this location. Several websites can be used to examine the
level of conservation of amino acids or nucleotides
(GERP, PhastCons and PhyloP). Recommended.
7. The variant affects a site in the protein that is predicted to
cause a functional defect, through an effect on the collag-
enous sequence or by altering interactions with other
membrane proteins [64].
Functional studies are the most conclusive means
of confirming pathogenicity, but except for splicing
mutations, are rarely used in Alport syndrome [65].
8. In silico prediction of a pathogenic effect, using the
different characteristics of the substituted amino acid,
such as a Grantham score, or ‘biochemical difference’.
Web-based classification tools are generally 65–80%
accurate. Any in silico analysis should include at least
three different programmes ideally based on different
algorithms, such as Condel, Mutation Taster, SIFT,
Polyphen-2 etc. Predictions combined from such tools
are generally considered a single piece of evidence
since the algorithms often include the same variables
and are interdependent. Acceptable.
Splice site predictive algorithms are generally valid
when used correctly. Again, three different prediction
tools are recommended. Acceptable . Tools for
predicting exonic/intronic splice enhancers and inhibi-
tors have not been validated and are not currently
recommended.
Experimental evidence for pathogenicity [63]
This approach is rarely used in Alport syndrome to confirm
variant pathogenicity. It could take the form of gene disruption
where the variant is demonstrated to alter protein levels, splic-
ing or biochemical function, in a cell line or in vitro model
system. The variant can also be introduced into a cell line or
animal model to produce a similar phenotype ('recapitula-
tion'), or the phenotype in a mutated cell line or model organ-
ism can be rescued by a wild-type gene product or a knock-
down of the variant allele.
The descriptive terms ‘polymorphisms’ and ‘mutation’
are not favoured for DNA variants because of incorrect
presumptions of benign or pathogenic connotations re-
spectively. Alternative terms are ‘variant of no known
phenotype’, ‘variant of uncertain clinical significance’
and ‘pathogenic mutation’ in the UK; and ‘benign vari-
ant’, ‘variant of uncertain significance’ and ‘pathogenic
variant’ in the USA.
A pathogenicity grading system is used commonly (Table
3). Assessing pathogenicity remains problematic [63]. Prior
reports of a variant being pathogenic are not definitive. As
far as possible, published variants should be reassessed as
carefully as a laboratory’s own results. Even strong evidence
that a variant is deleterious and/or damaging does not equate
to disease-causing. Pathogenicity should be assessed by mul-
tiple independent methods. Results returned for clinical use
should highlight actionable findings but also clearly convey
uncertain or ambiguous findings together with the rationale
for these conclusions.
Strategy when only one pathogenic variant is found
in suspected autosomal recessive Alport syndrome
Typically, autosomal recessive disease occurs with two
pathogenic variants in trans in COL4A3 or COL4A4. A
heterozygous variant is unlikely to produce a lamellated
GBM and renal failure but combinations of variants in
COL4A3 and COL4A4 and in other podocyte-derived
genes may do so. When a heterozygous variant is identi-
fied, the clinical characteristics range from haematuria to
end-stage renal failure [60]. Some heterozygous variants
may be associated with extra-renal features [66, 67], and
treatment with ACE inhibitors also delays the onset of
end-stage renal disease [68].
Recommendation 7: Where only one pathogenic vari-
ant is found in suspected autosomal Alport syndrome,
this resultshould be reported using a genetic descrip-
tion rather than the term ‘autosomal dominant Alport
syndrome’ until the significance of these single vari-
ants is better understood. Thus a report might read: ‘A
heterozygous variant was found in the COL4A3 gene
and is considered pathogenic’ together with the basis
for this assessment.
Most individuals with heterozygous variants do not de-
velop renal failure. Where renal failure occurs, this may
be because of an additional undetected pathogenic variant
in an Alport gene, a further podocyte gene mutation, a
coincidental renal disease such as IgA glomerulonephritis
or FSGS, or an additional complication such as hyperten-
sion, diabetes, obesity or medication use. Alternatively,
the absence of protective factors may also be responsible
for renal failure in heterozygous individuals. Thus, one
family member with the heterozygous mutation may de-
velop renal failure but another with the same mutation
does not [69].
Biallelic and digenic mutations affect the clinical
phenotype in Alport syndrome
An allele is one of a pair of genes at a particular location on a
particular chromosome. Biallelic variants refer to variants in
two alleles, that is, on different chromosomes. In cis variants
are located on the same allele of a gene, that is, on the same
chromosome. In trans variants are found In trans variants are
found in the same gene but on opposite chromosomes.
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Digenic variants are two variants in different genes, for exam-
ple, in COL4A5 and COL4A3. The situation is even more
complicated for COL4A3 and COL4A4 because these genes
are located back-to-back on the same chromosome, and a
COL4A3 variant will always be inherited together with a
COL4A4 variant if they are in cis. If a COL4A3 and
COL4A4 variant are not inherited together, they are located
on different chromosomes or in trans.
There are increasing reports of biallelic and digenic vari-
ants in Alport syndrome. There are also examples of variants
in COL4A3 and COL4A4 in trans [17, 18], and a single report
of a woman with two pathogenic COL4A5 variants in trans
[70]. In trans mutations are confirmed when the parents are
each demonstrated to have one variant. Confirmation requires
testing the parents’ or siblings’ DNA.
It is important to know if an individual has two COL4A3 or
COL4A4 variants in cis or in trans because the corresponding
phenotypes are different (Fig. 1). Individuals with two
COL4A3 or COL4A4 variants in cis have a milder phenotype
than those with two in trans [18].
The inheritance of mutations in cis and trans is different
too. The offspring of an affected individual with two muta-
tions in cis inherits both mutant alleles or none, whereas the
offspring of individuals with mutations in trans inherit one,
but not both, defective alleles. On average, half the offspring
of a person with two in cis mutations inherit both mutant
alleles. In contrast, all the offspring of an individual with
two mutations in trans (and hence autosomal recessive
Alport syndrome) inherit one mutation, and typically develop
haematuria but not renal failure.
There are also reports of individuals with digenic mutations,
affecting COL4A3 and COL4A4 [16, 18], and that the clinical
features are then milder than where mutations both affect
COL4A3, or both affect COL4A4, causing autosomal recessive
Alport syndrome.
Other genes may modify the Alport clinical
phenotype (Table 4)
Now that the Alport genes are commonly sequenced in
gene panels for FSGS, further combinations of variants
are being identified. Thus COL4A5 , COL4A3 and
COL4A4 mutations are sometimes found together with
mutations in other podocyte genes including ACTN4,
NPHS2 and MYO1E [71–73].
FSGS often occurs secondary to Alport syndrome or a
heterozygous COL4A3 or COL4A4 mutation, and muta-
tions, especially R229Q in NPHS2 [74], may coexist with
heterozygous COL4A3 or COL4A4 mutations worsening
proteinuria [72]. Digenic mutations also exacerbate dis-
ease severity in other forms of renal disease [73].
Recommendation 8: All likely pathogenic variants
in the COL4A5, COL4A3 and COL4A4 genes
should be reported. These may be biallelic, digenic
or multiple. Thus, if a pathogenic variant is found
in COL4A5 and another in COL4A3, both should
be reported since each is likely to affect the pheno-
type. Notwithstanding, some variants cannot be
categorised and should remain as ‘variants of un-
known significance’.
Other genes that could be tested for pathogenic
variants when none is found in the Alport genes
(Table 5)
Other autosomal dominant causes of haematuria and renal
failure include:
& Diseases of the complement pathway genes. CFH and
other complement pathway mutations result in dense
Fig. 1 Inheritance of heterozygous COL4A3 or COL4A4 pathogenic
variants in cis or trans. a. Inheritance of two pathogenic or mutant
variants in cis, that is, in the same gene on the same chromosome, are
inherited together from the one parent. This means that, on average, half
the offspring inherit both mutant alleles in cis and have haematuria. b
Inheritance of two pathogenic variants in trans, that is in the same gene,
but on different chromosomes, are NOT inherited together. All offspring
then inherit onemutant variant only and have haematuria. c Inheritance of
two pathogenic variants from different parents means that, on average,
half the offspring inherited one mutant variant and have haematuria only,
and one in four offspring (25%) inherits two mutant variants in trans, and
have haematuria and renal failure (autosomal recessive Alport syndrome).
One offspring has nomutant variant and no haematuria. Filled-in symbols
have a clinical phenotype, of at least haematuria
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deposit disease (haematuria, proteinuria, renal failure, ret-
inal drusen [75]). Renal failure typically develops in the
late teenage years. There is no hearing loss. CFHR5 ne-
phropathy is caused by heterozygous duplication of exons
2 and 3 ofCFHR5, and presents with haematuria and renal
impairment [76].
& Fechtner syndrome, due to mutations inMYH9 (myosin
heavy chain) gene. This is an uncommon condition,
characterised by haematuria, renal failure sometimes,
hearing loss, and a lamellated GBM, but also neutrophil
inclusions, thrombocytopenia and large platelets [77].
The neutrophil inclusions may be overlooked and re-
quire examination of fresh blood films. The blood
changes are lifelong and diagnostic. There is minimal
bleeding risk.
& Fibronectin glomerulopathy. This is rare, with haematuria,
but mainly proteinuria and renal failure in adulthood. It is
caused by mutation in FN1 [78].
& Hereditary Angiopathy, Nephropathy and Cramps
(HANAC) syndrome. This is a rare disease caused by
COL4A1 mutations and characterised by haematuria,
kidney cysts and irregularly thickened tubular and
Bowman’s capsular membranes, together with retinal
angiopathy, neurovascular abnormalities and cramps
[79].
& IgA disease. About 15% of all cases of IgA disease have
another affected family member [80] and although GWAS
analyses have identified chromosomal loci, relatively few
genes have been identified [81].
& ‘SLE is slightly more common in family members and
manifests with haematuria, proteinuria or renal impairment.
Other diseases that result in kidney failure with hearing loss
include Bartter syndrome, Nail-patella syndrome, Fabry disease,
Branchio-Oto-Renal disease, Hypoparathyroidism, deafness and
renal failure (HDR) and some mitochondrial syndromes such as
MELAS [7]. Nail-patella syndrome (associated with LMX1β
mutations) has an irregular disrupted GBM [82] that may resem-
ble the Alport GBM (and probably results from reduced collagen
IV α3 and α4 expression [83]). However, this condition is dis-
tinguished by its nail and patella abnormalities, and association
with proteinuria rather than haematuria.
Recommendation 9: Where Alport syndrome is
suspected clinically but no pathogenic variant is found
in the Alport genes, it is worthwhile reconsidering the
clinical diagnosis before further genetic testing and
bioinformatics analysis.
In conclusion, Alport syndrome is common but often
unrecognised; some patients diagnosed with FSGS on renal
biopsy have underlying mutations in the COL4A3, COL4A4
or COL4A5 genes; the mode of inheritance can be difficult to
predict so all three Alport genes should be examined for var-
iants; and biallelic and digenic mutations may affect the renal
failure progression. Most pathogenic have variants in the
Alport genes can be detected with sequencing; some are due
to duplications, deletions or insertions and may need further,
Table 4 Potential modifiers in Alport syndrome
Gene Protein Function Disease
NPHS2 Podocin Podocyte foot process protein, lipid raft FSGS (p.Arg229Gln) (R229Q),
(E237Q, Glu237Gln) [72]
LAMA5 Laminin chain GBM constituent Proteinuria
LAMB2 Laminin chain GBM constituent Proteinuria
APO1E Apolipoprotein 1E Mediates binding, internalisation
and catabolism of lipoproteins
FSGS, lipoprotein glomerulopathy
CFHR5 Complement factor H-related 5 A regulator of complement activation HUS, DDD
ACTN4 α actinin 4 Cytoskeletal function FSGS
PODXL Podocalyxin-like Found in podocytes, involved in
cell adhesion and migration
Glomerulonephritis
WT1
(also known as NPHS4)
Wilms tumour protein 1 Involved in normal development
of the urogenital system
FSGS, Denys-Drash syndrome
TRPC6 Transient receptor potential
cation channel subfamily C
Receptor-activated Ca channel in
podocyte cell membrane
FSGS
CD2AP CD2-associated protein Scaffolding molecule that regulates
the actin cytoskeleton
FSGS
INF2 Inverted formin 2 Polymerisation and depolymerisation
of actin filaments
FSGS
See text for references
FSGS focal segmental glomerular sclerosis, DDD dense deposit disease, GBM glomerular basement membrane
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different tests; and the remaining undetected variants are usu-
ally caused by deep intronic splicing or mosaicism.
Increasingly, compound heterozygous variants that include
not only the Alport genes but also genes encoding other
podocyte proteins.
Recommendation 10: Laboratories that test for genetic
variants in Alport syndrome continue to collect and
share their variants in variant databases [84]. The sub-
mission should include clinical features, an assessment
of pathogenicity and the basis of this decision, as well
as contact details of the submitting laboratory
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